The present invention is generally directed to non-surgical devices for the correction of skin contour defects and aging and is more particularly directed to an injection device for enabling introduction of a dermal filler into peripheral locations of a human body through a cannula.
Dermal fillers such as, such as Juvederm™, a hyaluronic acid based formulation, have been used for the treatment of nasal labial folds, lip augmentation, tear troughs, and for facial volumizing through the use of very fine syringe needles.
The dermal fillers are of high viscosity and this provides for effective, and preferably substantially uniform, suspension of the dermal filler into a peripheral location.
A relatively small needle size, gauge, is preferred for delivery of the dermal filler in order to lessen complications and recovery time. However, in combination with the relatively high viscosity of the dermal filler, a problem can arise with regard to needle assembly separation from the syringe due to the high pressure generated by a piston reacting on the high viscosity dermal filler in order to eject the filler from the syringe through a fine needle and into the patient.
The present invention overcomes this problem by providing an ejection device which eliminates, or substantially reduces, the probability of needle assembly/syringe separation during a procedure.
An injection device in accordance with the present invention generally includes a syringe having a body with a piston disposed therein and an open distal end.
A needle assembly is provided which includes a cannula and a luer connector engagable with the syringe distal end. The needle or cannula, hereinafter “cannula”, has a gauge of about 18 to a gauge of about 25 or greater. The luer connector includes a hub with a distal end supporting the cannula and a proximal end matable with the syringe distal end.
In one embodiment, the present invention further includes a viscous fluid, for example, a hyaluronic acid-based dermal filler, disposed in the syringe's body and which is injectable by the piston into a peripheral location of a human or animal body through the cannula.
The mating engagement, for example, between the hub and the syringe distal end is provided by internal threads disposed in the syringe distal end and external threads disposed on the hub, as well as between a tapered syringe cone and a tapered inside surface of the hub. The internal threads have a pitch which is sufficient to prevent detachment of the hub from syringe distal end during injection of the viscous fluid into a peripheral location of a human or animal body.
More particularly, in one embodiment, the internal threads have a pitch of between about 2 mm and about 5 mm. For example, the internal threads have a pitch of about 3 mm. The internal thread may be double lead screw threads. In addition, the external threads disposed on the hub further may also be double lead screw threads and the double lead screw threads provide an advantage of enabling the hub to travel twice the distance into mating engagement with the syringe distal end with each single turn of the hub. In other embodiments, the internal threads have a pitch of about 2.0 mm, about 3.0 mm, about 3.5 mm, about 4 mm, about 4.5 mm or about 5 mm. In addition, the external threads may have a pitch of about 2.0 mm, about 3.0 mm, about 3.5 mm, about 4 mm, about 4.5 mm or about 5 mm.
In a specific embodiment, the external threads comprise single circumference double lead screw threads as will be hereinafter described in greater detail.
In addition, a cavity, for example, a stepped cavity, is disposed in the hub. The cavity serves not only reduces dead space in the syringe but also significantly reduces the possibility of detachment of the hub from the syringe distal end during operation of the piston to eject the viscous fluid through the cannula. Thus, the cavity can be considered a hub retention cavity.
The advantages and features of the present invention will be better understood by the following description when considered in conjunction with the accompanying drawings in which:
With reference to
With additional reference to
Internal threads 52, 54 and external threads 56, 58 enable the mating engagement. Pitch (P) of the threads 52, 54 enables the ejection of viscous fluid 62 through the cannula 30 upon operation of the piston 18 without separation of the hub 42 from the syringe open distal end 22 during ejection of the viscous fluid 62 as illustrated in
In some embodiments, the viscous fluid 62 is a dermal filler. In some embodiments, the viscous fluid is a hyaluronic acid-based fluid having a viscosity between about 50,000 cps and about 500,000 cps, measured at about 25° C. with a controlled stress rheometer (RS600 TA Instrument) and a cone plate geometry (40 mm, 2°). In some embodiments, the viscous fluid is a hyaluronic acid based dermal filler having a viscosity greater than about 130,000 cps.
When measured with a traction column test (Versatest, Mecmesin), at 13 mm/min (extrusion speed) and a needle with a gauge between 21 G to 32 G, the viscous fluid may have an extrusion force of between about 5N up to about 200N, more specifically, an extrusion force of between about 10N to about 150N.
In an exemplary embodiment, the pitch of the hub threads 56, 58 is between about 2 mm and about 5 mm. Preferably, the pitch is about 3 mm. The threads 52, 54 and 56, 58 are preferably at least double lead screw threads, although triple, and even quadruple lead threads may used. As most clearly shown in
As hereinabove noted, this enables rapid engagement of the hub 42 with the syringe open distal end 22.
In one embodiment, the hub 42 is formed from a low elasticity material, for example, an acrylic or a polycarbonate, rather than polypropylene typically used for syringe hubs, as hereinafter described in connection with needle retention tests. This further enhances the prevention of detachment of the hub 46 from the syringe open distal end 22.
With reference to
The step 88 unexpectedly prevents or substantially reduces the possibility of detachment of the hub 42 from the syringe cone 90 and syringe open distal end 22 during injection of the viscous fluid 62.
That is, the average detachment force is significantly greater with the step 88 formed in the cavity hub retention cavity 80 of the hub 42 as was discovered during comparison study as follows:
Test methods used in this study utilized equipment designed by Omnica Corporation specifically for torque setting and detachment testing.
The torque set unit utilizes a numerically controlled motor and torque sensor which tightens the needle hub 42 onto the syringe open distal end 22 and a pre-determined torque setting testing is shown that the static friction between the needle hub 42 and the syringe open distal end 22 materials causes more overshoot than observed with standard polypropylene hubs (not shown).
A detachment tester utilizes a numerically controlled motor driving linear carriage against a forced transducer.
In a comparison test, all of the hubs (not shown) were attached to the syringe open distal end 22 and cone 90 with a torque of 0.07 Nm (Newton meter). All of the tests were performed on 0.8 cc syringes having identical dimensions, for example, syringe open distal end 22 having an entry diameter D (see
The results are shown in Table 1 for nominal torque static test needle retention with various design attribute combinations.
Table 1 shows that the conventional polypropylene hub mated to a syringe with 5 mm threads has an average detachment force 46.1 N (Newton) when the hub is attached to the syringe with a force of 0.07 Nm.
Slight improvement shown in the conventional polypropylene hub attached to the syringe body with 3 mm threads, and an average detachment force of about 56.2 N.
Utilizing polycarbonate instead of polypropylene for the hub 42 results in an average detachment force of 83.2 N with 5 mm threads utilized for attachment.
Combination of polycarbonate hub 42 with 3 mm threads without a step 88 results in a 96 N average detachment force.
Surprisingly, the detachment force for the hub 42 with 3 mm threads incorporating the dead space reducing step 88 results in an average detachment force of more than 200 N.
It is contemplated that other structures may be useful in reducing dead space in a manner effective to increase detachment force relative to conventional syringe/needle combinations. For example, it is contemplated that reduced dead space can be accomplished, within the scope of the present invention, by reducing an outer diameter of the syringe luer tip, increasing an inner diameter of the hub cavity, and/or other ways effective to increase the engagement length of the syringe tip and the hub.
A multi-center, double-blind, randomized parallel-controlled prospective comparison study was undertaken to test needle disengagement rates. This study tested needle disengagement rates of a Polycarbonate Hub and Syringe with 3 mm Threads and Stepped Cavity in accordance with the present invention (study device) in comparison to a conventional polypropylene hub and syringe with 5 mm threads (conventional device). Needles of each of the conventional devices and the study devices tested were all 30 G×½″ needles. The material injected for the study was Juvederm™ Ultra Injectable Gel (dermal filler).
There were up to 288 study participants. Each study participant underwent treatment for improving his or her bilateral nasolabial folds using 2 syringes of dermal filler packaged in either the conventional device or the study device.
The results demonstrated a significant difference in needle disengagement rates between the conventional device and the study device. No disengagements were reported for the study device. Between 3% and 7% of the needles of the conventional device unintentionally disengaged during injection.
Although there has been hereinabove described a specific injection device in accordance with the present invention for the purpose of illustrating the manner in which the invention may be used to advantage, it should be appreciated that the invention is not limited thereto. That is, the present invention may suitably comprise, consist of, or consist essentially of the recited elements. Further, the invention illustratively disclosed herein suitably may be practiced in the absence of any element which is not specifically disclosed herein. Accordingly, any and all modifications, variations or equivalent arrangements which may occur to those skilled in the art, should be considered to be within the scope of the present invention as defined in the appended claims.
This application claims the benefit of U.S. Provisional Patent Application No. 61/119,298, filed on Dec. 2, 2008 and U.S. Provisional Patent Application No. 61/139,430, filed on Dec. 19, 2008, the entire disclosure of each of which is incorporated herein by this specific reference.
Number | Name | Date | Kind |
---|---|---|---|
2737946 | Hein, Jr. | Mar 1956 | A |
2853070 | Maurice | Sep 1958 | A |
D202754 | Naftolin | Nov 1965 | S |
D214112 | Langdon | May 1969 | S |
D224066 | McDonald | Jun 1972 | S |
3720211 | Kyrias | Mar 1973 | A |
3807048 | Malmin | Apr 1974 | A |
4240423 | Akhavi | Dec 1980 | A |
4240426 | Akhavi | Dec 1980 | A |
4273122 | Whitney et al. | Jun 1981 | A |
4326517 | Whitney et al. | Apr 1982 | A |
4529401 | Leslie et al. | Jul 1985 | A |
4699612 | Hamacher | Oct 1987 | A |
D303010 | Jabbusch | Aug 1989 | S |
4869717 | Adair | Sep 1989 | A |
5024656 | Gasaway et al. | Jun 1991 | A |
5046506 | Singer | Sep 1991 | A |
5100390 | Lubeck et al. | Mar 1992 | A |
5104375 | Lubeck et al. | Mar 1992 | A |
5127436 | Campion et al. | Jul 1992 | A |
5141496 | Dalto et al. | Aug 1992 | A |
5295980 | Ersek | Mar 1994 | A |
5305788 | Mayeux | Apr 1994 | A |
5322511 | Armbruster et al. | Jun 1994 | A |
5344407 | Ryan | Sep 1994 | A |
5383851 | Mackinnon, Jr. et al. | Jan 1995 | A |
5405330 | Zunitch et al. | Apr 1995 | A |
D378939 | Smith et al. | Apr 1997 | S |
5690618 | Smith et al. | Nov 1997 | A |
5817033 | DeSantis | Oct 1998 | A |
5964737 | Caizza | Oct 1999 | A |
D424194 | Holdaway et al. | May 2000 | S |
D441077 | Garito et al. | Apr 2001 | S |
6231552 | Jentzen | May 2001 | B1 |
6432046 | Yarush et al. | Aug 2002 | B1 |
6595960 | West et al. | Jul 2003 | B2 |
6613010 | Castellano | Sep 2003 | B2 |
6616448 | Friedman | Sep 2003 | B2 |
D483116 | Castellano | Dec 2003 | S |
6689095 | Garitano et al. | Feb 2004 | B1 |
6783514 | Tovey et al. | Aug 2004 | B2 |
6824526 | Castellano | Nov 2004 | B2 |
7018356 | Wise et al. | Mar 2006 | B2 |
7419472 | Hibner et al. | Sep 2008 | B2 |
7494473 | Eggers et al. | Feb 2009 | B2 |
D615192 | Mudd et al. | May 2010 | S |
7878981 | Strother et al. | Feb 2011 | B2 |
D637287 | Mudd et al. | May 2011 | S |
8029460 | Rush et al. | Oct 2011 | B2 |
8066629 | Dlugos | Nov 2011 | B2 |
8480630 | Mudd et al. | Jul 2013 | B2 |
8603028 | Mudd et al. | Dec 2013 | B2 |
20020010433 | Johnson | Jan 2002 | A1 |
20020151843 | Correa et al. | Oct 2002 | A1 |
20030144632 | Hommann et al. | Jul 2003 | A1 |
20030199883 | Laks | Oct 2003 | A1 |
20040015133 | Karim | Jan 2004 | A1 |
20040092927 | Podhajsky et al. | May 2004 | A1 |
20040147883 | Tsai | Jul 2004 | A1 |
20040220532 | Caizza | Nov 2004 | A1 |
20050085767 | Menassa | Apr 2005 | A1 |
20050131353 | Mossanen-Shams et al. | Jun 2005 | A1 |
20050137496 | Walsh et al. | Jun 2005 | A1 |
20050261633 | Khalaj | Nov 2005 | A1 |
20060079765 | Neer | Apr 2006 | A1 |
20060089594 | Landau | Apr 2006 | A1 |
20070083155 | Muller | Apr 2007 | A1 |
20070100363 | Dollar et al. | May 2007 | A1 |
20070212385 | David | Sep 2007 | A1 |
20070250010 | Hohlfelder et al. | Oct 2007 | A1 |
20080033347 | D'Arrigo et al. | Feb 2008 | A1 |
20080097325 | Tanaka et al. | Apr 2008 | A1 |
20080108952 | Horvath et al. | May 2008 | A1 |
20080188816 | Shimazaki | Aug 2008 | A1 |
20080200758 | Orbay et al. | Aug 2008 | A1 |
20090088703 | Azar | Apr 2009 | A1 |
20090124996 | Heneveld et al. | May 2009 | A1 |
20090143746 | Mudd et al. | Jun 2009 | A1 |
20090240200 | Heneveld et al. | Sep 2009 | A1 |
20090299328 | Mudd et al. | Dec 2009 | A1 |
20100069848 | Alferness et al. | Mar 2010 | A1 |
20100152675 | McClintock | Jun 2010 | A1 |
20100280488 | Pruitt et al. | Nov 2010 | A1 |
20100282774 | Greter et al. | Nov 2010 | A1 |
20110021905 | Patrick et al. | Jan 2011 | A1 |
20110092916 | Tezel et al. | Apr 2011 | A1 |
20110137286 | Mudd et al. | Jun 2011 | A1 |
20110160674 | Holmes et al. | Jun 2011 | A1 |
20130131632 | Mudd et al. | May 2013 | A1 |
20130131633 | Mudd et al. | May 2013 | A1 |
20130274670 | Mudd et al. | Oct 2013 | A1 |
Number | Date | Country |
---|---|---|
0362484 | Apr 1990 | EP |
1051988 | Nov 2000 | EP |
1051988 | Nov 2000 | EP |
1486218 | Dec 2004 | EP |
1859827 | Nov 2007 | EP |
1923086 | May 2008 | EP |
2335755 | Jun 2011 | EP |
2622457 | May 1989 | FR |
WO 1999048601 | Sep 1999 | WO |
2005095225 | Oct 2005 | WO |
WO 2008019265 | Feb 2008 | WO |
WO 2008079824 | Jul 2008 | WO |
WO 2009098666 | Aug 2009 | WO |
WO 2009158145 | Dec 2009 | WO |
Entry |
---|
Davidenko et al., “Collagen-hyaluronic acid scaffolds for adipose tissue engineering”, ACTA Biomaterialia, vol. 6, No. 10, Oct. 1, 2010, pp. 3957-3968, XP055055114. |
Park et al., “Biological characterization of EDC-crosslinked collagen-hyaluronic acid matrix in dermal tissue restoration”, Biomaterials, Elsevier Science Publishiers BV, vol. 24, No. 9, Apr. 1, 2003, pp. 1631-1641, XP004404219. |
Wang et al., “In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermall filler injections in photodamaged human skin.”, Archives of Dermatology, American Medical Association, US, vol. 143, No. 2, Feb. 1, 2007, pp. 155-163, XP002574140. |
Number | Date | Country | |
---|---|---|---|
20100152679 A1 | Jun 2010 | US |
Number | Date | Country | |
---|---|---|---|
61139430 | Dec 2008 | US | |
61119298 | Dec 2008 | US |